CDH1 & Colon Cancer: What Are the Screening Guidelines?
At a Glance
A CDH1 or CTNNA1 mutation does not significantly increase your risk for colon cancer. Your colonoscopy screening schedule should be based on your family history of colon cancer rather than your mutation status. Those without a family history can generally start routine screening at age 45.
In this answer
3 sections
Having a CDH1 or CTNNA1 mutation does not mean you will probably get colon cancer. While these genetic changes are the primary drivers of Hereditary Diffuse Gastric Cancer (HDGC) and significantly increase your risk for stomach and lobular breast cancers [1][2], the evidence regarding colorectal cancer is very different. Current research indicates that your risk for colon cancer is generally similar to, or only slightly higher than, the average person [3][4]. Therefore, your timeline for starting colonoscopies depends heavily on your family history rather than your mutation status alone.
Your Actual Risk for Colon Cancer
It is common for patients facing multiple cancer risks to worry that a CDH1 mutation means high risks across the board. However, the scientific consensus is reassuring regarding the colon:
- Not a primary driver: Unlike Lynch syndrome, which directly causes high rates of colorectal cancer, CDH1 and CTNNA1 are not currently recognized as primary drivers of hereditary colon cancer [5][6].
- Polyp detection: Some recent studies suggest that people with CDH1 mutations might develop adenomas (benign colon polyps) at slightly higher rates than the general population [3][7]. However, the clinical significance of this is still being investigated, and it does not translate to a definitively high risk of actual cancer [4][7].
- CTNNA1 carriers: The CTNNA1 gene is recognized as a moderate-penetrance gene for HDGC (meaning it increases disease risk, but not as severely as CDH1), and its management closely mirrors that of CDH1 [8][9]. The same colon cancer risk and screening protocols apply [10].
Colonoscopy Screening Guidelines
Because the baseline risk for colon cancer is not drastically elevated by the mutation itself, the International Gastric Cancer Linkage Consortium (IGCLC) guidelines base their colonoscopy recommendations on your family history [1]. Because CDH1 and CTNNA1 mutations are rare, it is often helpful to bring a copy of the IGCLC guidelines to your gastroenterologist so they do not incorrectly assume you need aggressive, Lynch-syndrome-style screening.
If you have a family history of colon cancer
If a first-degree relative (such as a parent, sibling, or child) has been diagnosed with colon cancer, your screening needs to be more proactive. The IGCLC guidelines recommend:
- When to start: Age 40, OR 10 years before the earliest colon cancer diagnosis in your family — whichever comes first [1].
- Frequency: You should repeat the colonoscopy every 3 to 5 years [1].
If you DO NOT have a family history of colon cancer
If there is no history of colon cancer in your family, you do not need early, specialized colon screenings just because of your CDH1 or CTNNA1 mutation.
- When to start: Follow standard guidelines for average-risk adults, which typically means starting at age 45 [11][1]. This assumes you do not have other personal risk factors, such as a history of Inflammatory Bowel Disease (IBD).
- Frequency: If your first colonoscopy is entirely clear of polyps, you will likely only need them every 10 years, according to standard general population guidelines [1]. If polyps are found, your doctor will shorten this interval.
Managing Symptoms After Gastrectomy
Regardless of your family history, you should remain vigilant for early-onset symptoms [3]. However, if you have had a prophylactic total gastrectomy, you are likely already living with frequent bowel habit changes (like dumping syndrome) or abdominal discomfort. Do not panic every time you have an upset stomach. Instead, talk to your doctor about symptoms that are new, progressively worsening, or distinctly different from your usual post-surgery digestive baseline.
Practical Tip for Colonoscopy Prep: If you no longer have a stomach, drinking large volumes of colonoscopy prep fluid can be physically challenging or impossible. Speak to your gastroenterologist well in advance about prescribing a low-volume prep option, using pill-based preps, or extending the timeframe to slowly sip the fluids.
Common questions in this guide
Does a CDH1 mutation increase my risk of colon cancer?
When should CDH1 carriers start getting colonoscopies?
How often do I need a colonoscopy if I have a CDH1 mutation?
How do I prep for a colonoscopy after a prophylactic total gastrectomy?
Are CTNNA1 mutation carriers at a higher risk for colon cancer?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific family history of colon cancer and polyps, when exactly do I need to schedule my first colonoscopy?
- 2.Since I am a CDH1 mutation carrier, would you like a copy of the IGCLC guidelines to review before creating my screening plan?
- 3.If you find benign polyps during my colonoscopy, how will that change my screening frequency compared to the standard recommendation?
- 4.I have had a total gastrectomy and cannot drink large amounts of liquid quickly; what low-volume or pill-based colonoscopy prep options can we use?
- 5.How can I differentiate between normal post-gastrectomy digestive changes and symptoms that warrant an immediate colon evaluation?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Hereditary diffuse gastric cancer: updated clinical practice guidelines.
Blair VR, McLeod M, Carneiro F, et al.
The Lancet. Oncology 2020; (21(8)):e386-e397 doi:10.1016/S1470-2045(20)30219-9.
PMID: 32758476 - 2
Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.
Gamble LA, Heller T, Davis JL
JAMA surgery 2021; (156(4)):387-392 doi:10.1001/jamasurg.2020.6155.
PMID: 33404644 - 3
Colonoscopy findings in CDH1 carriers from a multicenter international study.
Chatterjee A, Hüneburg R, Yang Q, et al.
Familial cancer 2025; (24(2)):44 doi:10.1007/s10689-025-00466-8.
PMID: 40323501 - 4
Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis.
Stanich PP, Elgindi D, Stoffel E, et al.
The American journal of gastroenterology 2022; (117(11)):1877-1879 doi:10.14309/ajg.0000000000001996.
PMID: 36087100 - 5
A Rare MSH2 Variant as a Candidate Marker for Lynch Syndrome II Screening in Tunisia: A Case of Diffuse Gastric Carcinoma.
Kabbage M, Ben Aissa-Haj J, Othman H, et al.
Genes 2022; (13(8)) doi:10.3390/genes13081355.
PMID: 36011265 - 6
CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment.
Luo W, Fedda F, Lynch P, Tan D
Frontiers in pharmacology 2018; (9()):1421 doi:10.3389/fphar.2018.01421.
PMID: 30568591 - 7
Association of CDH1 Germline Variants and Colon Polyp Phenotypes in Patients with Hereditary Diffuse Gastric Cancer.
Passi M, Gamble LA, Samaranayake SG, et al.
Gastro hep advances 2023; (2(2)):244-251 doi:10.1016/j.gastha.2022.10.006.
PMID: 36776716 - 8
Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls.
Lobo S, Dias A, Pedro AM, et al.
Gut 2026; (75(5)):872-885 doi:10.1136/gutjnl-2024-334601.
PMID: 40998418 - 9
Cancer predisposition and germline CTNNA1 variants.
Lobo S, Benusiglio PR, Coulet F, et al.
European journal of medical genetics 2021; (64(10)):104316 doi:10.1016/j.ejmg.2021.104316.
PMID: 34425242 - 10
Clinical implications of CTNNA1 germline mutations in asymptomatic carriers.
Benusiglio PR, Colas C, Guillerm E, et al.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2019; (22(4)):899-903 doi:10.1007/s10120-018-00907-7.
PMID: 30515673 - 11
Potential impact of family history-based screening guidelines on the detection of early-onset colorectal cancer.
Gupta S, Bharti B, Ahnen DJ, et al.
Cancer 2020; (126(13)):3013-3020 doi:10.1002/cncr.32851.
PMID: 32307706
This page explains colon cancer screening guidelines for CDH1 and CTNNA1 mutation carriers for educational purposes. Always consult your gastroenterologist or genetic counselor to create a personalized screening plan based on your family history.
Get notified when new evidence is published on Hereditary diffuse gastric cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.